Herewith a couple of items of pandemic news you may have missed: Who is helping whom with manufacturing? And the impact of US export bans in support of Pfizer on vaccine production elsewhere. Plus news briefs and a frippery. US … Continue reading →
Apologies for not getting out a pandemic Friday Update this week. I was distracted (you can perhaps guess why), incessantly refreshing the Pennsylvania and Georgia vote counts. And yesterday, after the news, I was building a playlist for the day. … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: Pfizer’s timeline for EUA application, normally apolitical science publications criticize the Trump administration, and the $16T cost of the pandemic in the US. Plus the accustomed frippery. Pfizer … Continue reading →
Herewith three items of Covid-19 news you may have missed this week: Neurologic symptoms are common, wrinkles in vaccine distribution, and a tracker for the White House superspreader events. Plus the accustomed frippery. Neurologic symptoms are common A study in … Continue reading →
The Washington Post reports that the FDA will soon release tough new standards for granting emergency authorization for any Covid-19 vaccine — standards that all but guarantee that none could get the green light before mid-November. It looks to me … Continue reading →
Nine vaccine makers have signed an unprecedented pledge to conduct the search for a Covid-19 vaccine only “in accordance with high ethical standards and sound scientific principles,” in an attempt to bolster public confidence in any vaccine that emerges. Political … Continue reading →
The President, always one to say the quiet parts out loud, has made no secret of wanting to announce a vaccine before November 3 in order to boost his chances for reelection. Let’s look at how that might be possible. … Continue reading →
